Published in J Clin Microbiol on February 01, 2001
Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob Agents Chemother (2011) 1.35
In-vitro and in-vivo evidence of dose-dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules. Clin Microbiol Infect (2008) 1.28
Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period. Antimicrob Agents Chemother (2002) 0.98
Antibiotic resistance in pediatric urology. Ther Adv Urol (2014) 0.81
Adverse outcomes in nursing home residents with increased episodes of observed bacteriuria. Infect Control Hosp Epidemiol (2010) 0.81
Value of an aggregate index in describing the impact of trends in antimicrobial resistance for Escherichia coli. Can J Infect Dis Med Microbiol (2015) 0.76
Biofilm formation, antimicrobial susceptibility, serogroups and virulence genes of uropathogenic E. coli isolated from clinical samples in Iran. Antimicrob Resist Infect Control (2016) 0.75
Antibiotic resistance in uropathogenic e. Coli strains isolated from non-hospitalized patients in pakistan. J Clin Diagn Res (2014) 0.75
Identification of Extended-Spectrum β-Lactamases Escherichia coli Strains Isolated from Market Garden Products and Irrigation Water in Benin. Biomed Res Int (2015) 0.75
Antibiotic resistance rates and physician antibiotic prescription patterns of uncomplicated urinary tract infections in southern Chinese primary care. PLoS One (2017) 0.75
CDC definitions for nosocomial infections, 1988. Am J Infect Control (1988) 27.03
Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA (1999) 4.69
Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 4.20
Antibiotic resistance in Spain: what can be done? Task Force of the General Direction for Health Planning of the Spanish Ministry of Health. Clin Infect Dis (1996) 2.94
Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother (1999) 2.89
Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother (1999) 2.80
Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother (1995) 2.62
Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother (1995) 2.56
Why are antibiotic resistance genes so resistant to elimination? Antimicrob Agents Chemother (1997) 2.32
A comparative study of nosocomial and community-acquired strains of Escherichia coli causing bacteraemia in a Danish University Hospital. J Hosp Infect (1995) 2.11
Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs (1999) 1.91
Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother (1995) 1.78
Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother (1994) 1.64
Risk factors for resistance to "first-line" antimicrobials among urinary tract isolates of Escherichia coli in children. CMAJ (1999) 1.61
Urinary tract infections in children. Epidemiology, evaluation, and management. Pediatr Clin North Am (1997) 1.57
Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol (1995) 1.44
Prevalence of bacterial resistance to quinolones and other antimicrobials among avian Escherichia coli strains isolated from septicemic and healthy chickens in Spain. J Clin Microbiol (1997) 1.42
The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women. Int J Antimicrob Agents (1999) 1.34
Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections. Eur J Clin Microbiol Infect Dis (1993) 1.30
Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. J Clin Microbiol (1996) 1.29
Changes in urinary pathogens and their antibiotic sensitivities, 1971-1992. J Antimicrob Chemother (1994) 1.17
Antimicrobial resistance patterns in urinary isolates from nursing home residents. Fifteen years of data reviewed. J Antimicrob Chemother (1999) 1.15
Antibiotic resistance in bacterial urinary tract infections, 1991 to 1997. West J Med (1998) 0.96
Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis (1998) 0.96
Development of antibacterial resistance: the Dutch experience. J Antimicrob Chemother (1994) 0.94
Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains. Clin Infect Dis (1999) 0.91
Antibiotic resistance. J Antimicrob Chemother (1998) 0.91
Increases in rates of resistance to trimethoprim. Clin Infect Dis (1997) 0.90
Use of amoxicillin-clavulanate and resistance in Escherichia coli over a 4-year period. Infect Control Hosp Epidemiol (1998) 0.90
Community-acquired urinary tract infection in adults: a hospital viewpoint. J Hosp Infect (1998) 0.88
Ciprofloxacin-resistant Escherichia coli emerging in a rehabilitation medical center. Diagn Microbiol Infect Dis (1997) 0.82
[Antibiogram Committee of the French Society for Microbiology. Official Statement 1999]. Pathol Biol (Paris) (1999) 0.81
[Urinary tract infection in an urban population: etiology and antibiotic sensitivity as a function of patient history]. Presse Med (1999) 0.79
[Antibiotic sensitivity to isolated bacteria in pediatric urinary tract infections]. Arch Pediatr (1998) 0.78
Use of low-frequency-cleavage restriction endonucleases for DNA analysis in epidemiological investigations of nosocomial bacterial infections. J Clin Microbiol (1989) 5.70
A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob Agents Chemother (2000) 3.47
Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Rev Infect Dis (1988) 3.35
Ophthalmic regional anesthesia: medial canthus episcleral (sub-tenon) anesthesia is more efficient than peribulbar anesthesia: A double-blind randomized study. Anesthesiology (2000) 3.24
Concomitant dissemination of three extended-spectrum beta-lactamases among different Enterobacteriaceae isolated in a French hospital. J Antimicrob Chemother (1991) 3.08
Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-->Gly. Antimicrob Agents Chemother (2001) 3.03
Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother (1999) 2.80
Characterization of the plasmid genes blaT-4 and blaT-5 which encode the broad-spectrum beta-lactamases TEM-4 and TEM-5 in enterobacteriaceae. Gene (1989) 2.69
Nucleotide sequences of CAZ-2, CAZ-6, and CAZ-7 beta-lactamase genes. Antimicrob Agents Chemother (1992) 2.62
Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother (1995) 2.56
Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis. Antimicrob Agents Chemother (2002) 2.31
A 1998 survey of extended-spectrum beta-lactamases in Enterobacteriaceae in France. The French Study Group. Antimicrob Agents Chemother (2000) 2.22
Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother (2003) 2.16
Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS (2000) 2.14
Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors. Antimicrob Agents Chemother (1994) 2.13
Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost (2005) 2.10
CTX-M-1, CTX-M-3, and CTX-M-14 beta-lactamases from Enterobacteriaceae isolated in France. Antimicrob Agents Chemother (2002) 2.09
Prospective survey of colonization and infection caused by expanded-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae in an intensive care unit. J Clin Microbiol (1989) 2.07
Diversity of TEM mutants in Proteus mirabilis. Antimicrob Agents Chemother (1999) 1.98
Clinical and bacteriological study of nosocomial infections due to Enterobacter aerogenes resistant to imipenem. J Clin Microbiol (1993) 1.94
Survey of prevalence of extended spectrum beta-lactamases among enterobacteriaceae. J Antimicrob Chemother (1996) 1.91
A novel class A extended-spectrum beta-lactamase (BES-1) in Serratia marcescens isolated in Brazil. Antimicrob Agents Chemother (2000) 1.86
Interactions of new plasmid-mediated beta-lactamases with third-generation cephalosporins. Rev Infect Dis (1988) 1.84
Molecular epidemiology of TEM-3 (CTX-1) beta-lactamase. Antimicrob Agents Chemother (1990) 1.73
Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol (2000) 1.70
DNA polymorphisms in methicillin-susceptible and methicillin-resistant strains of Staphylococcus aureus. J Clin Microbiol (1992) 1.67
R-plasmid-encoded adhesive factor in Klebsiella pneumoniae strains responsible for human nosocomial infections. Infect Immun (1992) 1.66
Selective interaction of AGS3 with G-proteins and the influence of AGS3 on the activation state of G-proteins. J Biol Chem (2001) 1.64
Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother (1994) 1.64
Characterization of an inhibitor-resistant enzyme IRT-2 derived from TEM-2 beta-lactamase produced by Proteus mirabilis strains. J Antimicrob Chemother (1996) 1.64
Chromosomally encoded ampC-type beta-lactamase in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother (1998) 1.61
Kinetic properties of two plasmid-mediated beta-lactamases from Klebsiella pneumoniae with strong activity against third-generation cephalosporins. J Antimicrob Chemother (1988) 1.54
Identification of CTX-2, a novel cefotaximase from a Salmonella mbandaka isolate. Antimicrob Agents Chemother (1991) 1.54
[Statistical regression analysis for four new cephalosporins (author's transl)]. Pathol Biol (Paris) (1982) 1.53
TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient. Antimicrob Agents Chemother (1999) 1.49
Clonal outbreaks of extended-spectrum beta-lactamase-producing strains of Klebsiella pneumoniae demonstrated by antibiotic susceptibility testing, beta-lactamase typing, and multilocus enzyme electrophoresis. J Clin Microbiol (1994) 1.46
First characterization of inhibitor-resistant TEM (IRT) beta-lactamases in Klebsiella pneumoniae strains. Antimicrob Agents Chemother (1995) 1.40
Intrapericardial bronchogenic cyst: an unusual cause of CA 19-9 increase. Eur J Med (1992) 1.39
TEM derivative-producing Enterobacter aerogenes strains: dissemination of a prevalent clone. Antimicrob Agents Chemother (2002) 1.32
Sequences of CAZ-3 and CTX-2 extended-spectrum beta-lactamase genes. Antimicrob Agents Chemother (1994) 1.29
Production of a TEM-24 plasmid-mediated extended-spectrum beta-lactamase by a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2000) 1.28
Mycobacterium haemophilum and mycobacterium xenopi associated infection in a renal transplant patient. Clin Nephrol (1985) 1.27
Release kinetics of serum cardiac troponin I in ischemic myocardial injury. Clin Biochem (1996) 1.26
Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of the Auvergne, France: a 2 year prospective study. J Antimicrob Chemother (2004) 1.26
A new fimbrial antigen harbored by CAZ-5/SHV-4-producing Klebsiella pneumoniae strains involved in nosocomial infections. Infect Immun (1996) 1.23
TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5). Antimicrob Agents Chemother (2005) 1.21
Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: a 2-year survey in a French hospital. Antimicrob Agents Chemother (2000) 1.20
Reduction of the severe sepsis or septic shock associated mortality by reinforcement of the recommendations bundle: a multicenter study. Ann Fr Anesth Reanim (2010) 1.18
A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. J Hosp Infect (1991) 1.15
Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost (2010) 1.14
Increased serum resistance in Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2004) 1.11
Clinical relevance of Proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother (2000) 1.10
Previously undescribed 6.6-kilobase R plasmid in penicillinase-producing Neisseria gonorrhoeae. Antimicrob Agents Chemother (1986) 1.08
Tick-borne infection caused by Rickettsia africae in the West Indies. N Engl J Med (1998) 1.08
Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect (2004) 1.06
Aneurysms complicating coarctation of the aorta: anatomic aspects and evolution. Report of six successful surgical cases. Thorac Cardiovasc Surg (1982) 1.04
A comparison of agar dilution, identification of beta-lactamases and disc diffusion methods for assessing the sensitivity to ticarcillin-clavulanic acid. J Antimicrob Chemother (1986) 1.04
New TEM variant (TEM-92) produced by Proteus mirabilis and Providencia stuartii isolates. Antimicrob Agents Chemother (2001) 1.03
Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling. Biochim Biophys Acta (1998) 1.02
Traumatic aortic regurgitation: aortic valvuloplasty controlled by aortoscopy. J Heart Valve Dis (2001) 1.01
[A severe epidemic of Streptococcus group G infection in hemodialysis: epidemiologic survey by molecular biology and preventive measures]. Nephrologie (1991) 1.01
Additional direct medical costs of nosocomial infections: an estimation from a cohort of patients in a French university hospital. J Hosp Infect (2008) 1.00
[The treatment of brucellosis using rifampicine (author's transl)]. Nouv Presse Med (1979) 1.00
Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244. Antimicrob Agents Chemother (1997) 1.00
Relationship between adhesion to intestinal Caco-2 cells and multidrug resistance in Klebsiella pneumoniae clinical isolates. J Clin Microbiol (1997) 0.96
Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum beta-lactamase CTX-M-9. Antimicrob Agents Chemother (2003) 0.96
Characterization of a beta-lactamase from Pasteurella multocida. Ann Inst Pasteur Microbiol (1988) 0.94
A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer. Am J Clin Oncol (1998) 0.94
Resistance to beta-lactams in Enterobacteriaceae: distribution of phenotypes related to beta-lactamase production. J Int Med Res (1986) 0.93
Micro-osteoclast resorption as a characteristic feature of B-cell malignancies other than multiple myeloma. Br J Haematol (1990) 0.93
Impact of medical recommendations on alcohol consumption in HCV positive patients. J Hepatol (2001) 0.92
Treatment of a meningitis due to an Enterobacter aerogenes producing a derepressed cephalosporinase and a Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Infection (1991) 0.91
Chromosomally-mediated beta-lactamases produced by Levinea amalonatica with activity against methoxyimino-cephalosporins. J Antimicrob Chemother (1991) 0.91
Novel plasmid-mediated ceftazidimase from Klebsiella pneumoniae isolates. J Antimicrob Chemother (1988) 0.91
The kinetics of SHV-2 plasmid-mediated beta-lactamase compared to those of the parent enzyme from which it is derived. Drugs Exp Clin Res (1988) 0.90
Identification of two novel TEM-derivative ceftazidimases, CAZ-6 and CAZ-7, from Klebsiella pneumoniae isolates. J Antimicrob Chemother (1989) 0.90
Effects of postoperative ketamine infusion on pain control and feeding behaviour in bitches undergoing mastectomy. J Small Anim Pract (2007) 0.90
Comparison of the diagnostic value of cardiac troponin I and T determinations for detecting early myocardial damage and the relationship with histological findings after isoprenaline-induced cardiac injury in rats. Clin Chim Acta (2000) 0.90
GSM radiocellular telephones do not disturb the secretion of antepituitary hormones in humans. Bioelectromagnetics (1998) 0.89
[Liver cirrhosis after 2 years of perhexiline maleate treatment]. Nouv Presse Med (1978) 0.89
Disposition of roxithromycin in the epididymis after repeated oral administration. J Antimicrob Chemother (1992) 0.88
Time-course of cardiac troponin I release from isolated perfused rat hearts during hypoxia/reoxygenation and ischemia/reperfusion. Clin Chim Acta (1999) 0.87
Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol (1990) 0.87
CK-MB mass test in ischemic myocardial injury. Comparison of two tests: BioMerieux Vidas and sanofi access immunoassays. J Clin Lab Anal (2000) 0.85
Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group. J Antimicrob Chemother (1995) 0.85
Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. Am J Cardiol (1999) 0.85
Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost (2010) 0.85
Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model. Clin Microbiol Infect (2005) 0.84
Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases. J Antimicrob Chemother (1989) 0.84
Surgical treatment of primitive ventricle and complex congenital heart malformation with total exclusion of the right heart: report of a case. J Thorac Cardiovasc Surg (1982) 0.84
Factors associated with antimicrobial resistance among clinical isolates of Klebsiella pneumoniae: 1-year survey in a French university hospital. Eur J Clin Microbiol Infect Dis (2004) 0.84
[Detection of extended-spectrum beta-lactamases by the rapid ATB E technique. Value of the API V2.1.1 expert system]. Pathol Biol (Paris) (1992) 0.84
Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins. J Antimicrob Chemother (1989) 0.84
Kinetics of detection of antibodies to HIV-1 and plasma p24 antigens during a severe primary HIV-1 infection. AIDS (1995) 0.83
Problems encountered in the characterization of IRT beta-lactamase-producing clinical Escherichia coli isolates intermediate-resistant to cephalothin. J Antimicrob Chemother (1996) 0.83
Impairment of respiratory burst in polymorphonuclear leukocytes by extended-spectrum beta-lactamase-producing strains of Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis (2003) 0.83
[Brucella melitensis endocarditis. Clinical and immunological features (author's transl)]. Sem Hop (1982) 0.83
Low plasma levels of dehydroepiandrosterone sulphate in HIV-positive patients coinfected with hepatitis C virus. HIV Med (2004) 0.83